Anteris Technologies Global Corp.

XNASHealth care

Last traded price · USD

$6.25

+2.12%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 19:04 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $6.12
Volume: 336
Day's high: —
Day's low: —

In brief

Anteris Technologies Global Corp. is a health care company listed on Nasdaq, valued at about $609M.
Its shares closed at $6.12 on 4 Nov 2026, up 43.3% over the past year.
From India you can buy AVR in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Anteris Technologies Global Corp. (AVR) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole AVR share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade AVR options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: −13.2% (SPY −1.6%, XLV +13.5%). 3 months: −24.0% (SPY −0.4%, XLV +15.5%). 1 year: +43.3% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: AVR, SPY and XLV · as of 4 Nov 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $6.12 was 17.0% below its 50-day average ($7.37) and 17.3% below its 200-day average ($7.40). It has closed below the 200-day for 22 sessions, since 6 Oct 2026. The 50-day average crossed below the 200-day on 4 Nov 2026, in the latest session.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Volume 2.9× its 30-session average on 2 Nov 2026
2 Nov 2026 volume of 4.0M shares was 2.9× the average of the 30 sessions before it (1.4M), as the price fell 8.4%. SPY traded 1.2× its own average that session.
Daily volume against a 30-session baseline · as of 2 Nov 2026
36% of the way up its 52-week range
Closed at $6.12 on 4 Nov 2026: 44.6% below the 52-week high of $11.06 (6 Jul 2026) and 85.5% above the low of $3.30 (21 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026
7.9M shares sold short
7.9M shares were sold short at the 15 Oct 2026 settlement; covering them would take 5.0 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−13.2%

6 months−4.2%

1 year+43.3%

5 years—

Newswire

About

Anteris Technologies Global Corp is a structural heart company focused on advancing cardiac care through science-driven innovations aimed at restoring heart valve patients to healthy function. Its key product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with interventional cardiologists and cardiac surgeons to treat Aortic Stenosis, a potentially life-threatening condition caused by narrowing of the aortic valve. The balloon-expandable DurAVR THV is a biomimetic valve designed to mimic the performance of a healthy human aortic valve and replicate normal aortic blood flow. The company operates in United States, Germany, Australia, Switzerland, and Sweden, with the majority of its revenue generated from the United States.

Website

Notable moves

October 20, 2025
+21.77%
May 27, 2025
+31.87%
April 23, 2025
+27.64%

Newswire

About

Website

Notable moves

October 20, 2025
+21.77%
May 27, 2025
+31.87%
April 23, 2025
+27.64%

Anteris Technologies Global Corp.

XNASHealth care

Last traded price · USD

$6.25

+2.12%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 19:04 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $6.12
Volume: 336
Day's high: —
Day's low: —

In brief

Anteris Technologies Global Corp. is a health care company listed on Nasdaq, valued at about $609M.
Its shares closed at $6.12 on 4 Nov 2026, up 43.3% over the past year.
From India you can buy AVR in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Anteris Technologies Global Corp. (AVR) shares from India?

Do I need the price of a whole AVR share to invest?

How much can I invest in US stocks in a year?

Can I trade AVR options or futures?

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: −13.2% (SPY −1.6%, XLV +13.5%). 3 months: −24.0% (SPY −0.4%, XLV +15.5%). 1 year: +43.3% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: AVR, SPY and XLV · as of 4 Nov 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $6.12 was 17.0% below its 50-day average ($7.37) and 17.3% below its 200-day average ($7.40). It has closed below the 200-day for 22 sessions, since 6 Oct 2026. The 50-day average crossed below the 200-day on 4 Nov 2026, in the latest session.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Volume 2.9× its 30-session average on 2 Nov 2026
2 Nov 2026 volume of 4.0M shares was 2.9× the average of the 30 sessions before it (1.4M), as the price fell 8.4%. SPY traded 1.2× its own average that session.
Daily volume against a 30-session baseline · as of 2 Nov 2026
36% of the way up its 52-week range
Closed at $6.12 on 4 Nov 2026: 44.6% below the 52-week high of $11.06 (6 Jul 2026) and 85.5% above the low of $3.30 (21 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026
7.9M shares sold short
7.9M shares were sold short at the 15 Oct 2026 settlement; covering them would take 5.0 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−13.2%

6 months−4.2%

1 year+43.3%

5 years—

Newswire

About

Website

Notable moves

October 20, 2025
+21.77%
May 27, 2025
+31.87%
April 23, 2025
+27.64%

Newswire

About

Website

Notable moves

October 20, 2025
+21.77%
May 27, 2025
+31.87%
April 23, 2025
+27.64%

Anteris Technologies Global Corp.

Anteris Technologies Global Corp. in brief

Ahead of SPY and its sector fund XLV over 1 year

Below its 50- and 200-day averages

Volume 2.9× its 30-session average on 2 Nov 2026

36% of the way up its 52-week range

7.9M shares sold short

Anteris Technologies Global Corp.

Anteris Technologies Global Corp. in brief

Ahead of SPY and its sector fund XLV over 1 year

Below its 50- and 200-day averages

Volume 2.9× its 30-session average on 2 Nov 2026

36% of the way up its 52-week range

7.9M shares sold short